Tearing Down the Barrier of Prior Authorization Through Automation

If you’ve ever had to chase down a prior authorization before getting your medical procedure approved for coverage, you’re not alone. According to a recent white paper by the American Hospital Association, prior authorization has been found to be a barrier to care, restricting access to coverage for many patients. Paul Shorrosh, founder and CEO of AccuReg is here to change that. Shorrosh sits down with host Kevin Stevenson to talk about the importance of pushing for change and adapting prior authorization automation.

According to Shorrosh, automating prior authorization helps hospitals and health systems integrate patient engagement, intake, and access to enable increased revenue. However, insurers have generally refused to automate. Instead, insurers have stayed old school, “So what they use is fax machines, phone calls, emails, and web portals,” said Shorrosh.

Prior authorization not only prevents patient care but often results in unpaid bills and coverage denials, “So nothing good comes out of that process especially when a lot of those procedures could be approved by the payer in advance if it were an easier, more automated modern process,” stated Shorrosh.

Given there is an existing industry standard, the 278 standard, for electronic authorization, widespread automation should not be an issue. However, Shorrosh said insurers are not being “held accountable to use it.”

Shorrosh’s solution is to use a best practice approach involving five steps, in order:

  1. Identity and demographic validation
  2. Eligibility and benefit verification
  3. Prior authorization requirement check
  4. Submission management platform; submit request to payer
  5. Retrieving authorization and status

Shorrosh said, “We’re not even asking the payers to reduce their requirements,” but pushing for change in an industry that is slow to adapt.

To encourage this, Shorrosh said, “I hope that CMS and government entities will help with that, make this electronic.”

Automating the prior authorization process not only improves speed of acceptance, but ultimately helps the patient.

More Like This Story:

Best-Selling Author Uses Art To To Teach Interpersonal Development

How To Navigate the American Healthcare System

Follow us on social media for the latest updates in B2B!

Image

Latest

cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More
organoids
Growing the Future of Cancer Research: Inside the Promise of Organoids
April 19, 2025

In an era where precision and predictability define the future of oncology, organoid technology is emerging as a transformative tool in drug discovery. These miniature, lab-grown 3D tissues mirror real human biology more closely than traditional 2D models or even animal systems, offering researchers the potential to predict patient-specific drug responses. As organoids become more…

Read More